Germany’s Merck KGaA has partnered with techbio company Caris Discovery in a $1.4 billion alliance that will apply artificial intelligence to the design of antibody-drug conjugates (ADCs) for cancer.
The deal between Caris and Merck’s US subsidiary EMD Serono includes an undisclosed upfront payment as well as research funding, along with discovery, development, regulatory and sales-based milestone payments and royalties on the sales of any ADCs that make it to market.
